Vertex announces Phase 3 RAINIER results for povetacicept in IgA nephropathy published in NEJM

Vertex Pharmaceuticals announced Phase 3 RAINIER results supporting the potential of povetacicept in IgA nephropathy, published in the New England Journal of Medicine. Povetacicept showed a 49.8% greater proteinuria reduction versus placebo in the Phase 3 IgAN trial, with an FDA decision expected November 30.

Detected & updated continuously · Source: Nebula